Free Trial

IQVIA (IQV) Stock Forecast & Price Target

$219.09
-3.36 (-1.51%)
(As of 05/31/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Consensus Price Target

$257.57
17.56% Upside
High Forecast$300.00
Average Forecast$257.57
Low Forecast$220.00
TypeCurrent Forecast
6/3/23 to 6/2/24
1 Month Ago
5/4/23 to 5/3/24
3 Months Ago
3/5/23 to 3/4/24
1 Year Ago
6/3/22 to 6/3/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
11 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$257.57$257.57$256.80$253.25
Forecasted Upside17.56% Upside17.73% Upside15.67% Upside21.06% Upside
Get IQVIA Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.70
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside17.56% Upside761.59% Upside9.98% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/3/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$275.00 ➝ $250.00+11.41%
5/3/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$297.00 ➝ $292.00+29.83%
5/3/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$254.00 ➝ $245.00+10.29%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$290.00+17.29%
2/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $300.00+24.99%
2/15/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $265.00+8.83%
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
2/13/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$285.00+30.81%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$190.00 ➝ $225.00+4.52%
11/13/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$262.00 ➝ $239.00+23.73%
11/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$240.00 ➝ $225.00+18.11%
10/10/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$250.00 ➝ $229.00+14.76%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$260.00+17.71%
8/2/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $281.00+28.44%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$235.00 ➝ $220.00+16.88%
2/13/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$265.00+14.17%
12/6/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$251.00+18.44%
10/18/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$290.00 ➝ $270.00+49.02%
8/18/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$260.00 ➝ $275.00+15.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:49 PM ET.

IQV Frequently Asked Questions

What is IQVIA's stock forecast and purchase recommendation?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $257.57, with a high forecast of $300.00 and a low forecast of $220.00. The consensus rating for IQVIA stock is Moderate Buy based on the current 3 hold ratings and 12 buy ratings for IQV. Learn more on IQV's analyst rating history.

Do Wall Street analysts like IQVIA more than its competitors?

Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.80 while the average consensus rating score for "medical" companies is 2.70. Learn more on how IQV compares to other companies.

Does IQVIA's stock price have much upside?

According to analysts, IQVIA's stock has a predicted upside of 17.73% based on their 12-month stock forecasts.

What analysts cover IQVIA?

IQVIA has been rated by research analysts at Evercore ISI, Robert W. Baird, and Truist Financial in the past 90 days.


Stock Forecasts and Research Tools

This page (NYSE:IQV) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners